ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,881.63
-0.43%
Dow Jones
42,544.22
-0.07%
US Dollar vs MXN
20.86848
1.07%
Brent Oil
74.85
1.01%
Bitcoin
93,398.88
0.79%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. PMV Pharmaceuticals Inc (PMVP)

  7. PMV Pharmaceuticals Inc (PMVP) Noticias

PMV Pharmaceuticals Inc

PMV Pharmaceuticals Inc (PMVP)

NASDAQ
1.51
0.02
(1.34%)
Al cierre: 31 Diciembre 3:00PM
Delayed by 15 minutes
1.51
0.00
( 0.00% )
Fuera de horario: 4:15PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

PMVP Noticias

Solo noticias oficiales

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
28 Noviembre 2024
PMVP (1.34%)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Edgar (US Regulatory)
27 Noviembre 2024
PMVP (1.34%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
20 Noviembre 2024
PMVP (1.34%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 Noviembre 2024
PMVP (1.34%)

Form 8-K - Current report
Edgar (US Regulatory)
07 Noviembre 2024
PMVP (1.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 Octubre 2024
PMVP (1.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 Octubre 2024
PMVP (1.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
12 Septiembre 2024
PMVP (1.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
12 Septiembre 2024
PMVP (1.34%)

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
Edgar (US Regulatory)
14 Agosto 2024
PMVP (1.34%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
08 Agosto 2024
PMVP (1.34%)

Form 8-K - Current report
Edgar (US Regulatory)
08 Agosto 2024
PMVP (1.34%)

PMVP Discussion

Ver más
Monksdream Monksdream 9 meses hace
PMVP under $2
👍️0
Mt. Blanc Mt. Blanc 11 meses hace
PMVP had a great move over $3 but then lost control of the jet and sank quickly.
👍️0
Mt. Blanc Mt. Blanc 1 año hace
PMVP into the cup and handle chart setup. On radar to begin climbing the great wall of worry.

mb
👍️0
Mt. Blanc Mt. Blanc 1 año hace
$PMVP trading in the low $2's for now but at some point, this starts to firm up well into 2024+.

mb
👍️0
Mt. Blanc Mt. Blanc 1 año hace
PMVP will be under radar for a while until it catches fire and then will be seen.

mb
👍️0
crudeoil24 crudeoil24 3 años hace
2022 American Society of Clinical Oncology (ASCO) Annual Meeting
👍️0
crudeoil24 crudeoil24 3 años hace
JUNE 7 > Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented .
👍️0
crudeoil24 crudeoil24 3 años hace
PMV Pharma Shares Rise 17%; Company to Present Data on PYNNACLE Phase 1 Trial
6:46 pm ET May 26, 2022 (Dow Jones) Print

By Stephen Nakrosis


Shares of PMV Pharmaceuticals Inc. were trading higher in Thursday's after-hours market, following the company's announcement that it would be presenting data from its lead program, PC14586, at the 2022 American Society of Clinical Oncology meeting next month.

PMV said its abstract describes "preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation." PMV said the preliminary results "represent the first clinical evidence of targeting a p53 Y220C mutation."

At 6:37 p.m. ET, PMV's shares were trading 17.79% higher at $15.56 a share. Volume at the time topped 2.1 million shares. The company's stock finished the day with a 0.92% gain, closing at $13.21 a share.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

PMVP
👍️0
crudeoil24 crudeoil24 3 años hace
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.

PMVP
👍️0

Su Consulta Reciente

NASDAQ
PMVP
PMV Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados